Who
Gregory A. Demopulos
Chairman, CEO & President
Company insider
Files Form 4 as: Chairman, CEO & President, Omeros.
In numbers
- Trades disclosed
- 94
- Buys
- 1
- Sells
- 12
- Bought
- $25K
- Sold
- $10.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Apr 2010
- Last trade
- 22 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 24 Jul 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 22 Jul 2026filed 24 Jul 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $4.1M400,000 at $10.27 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code F | $4.3M357,678 at $11.93 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —400,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —400,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $4.1M400,000 at $10.27 | filing |
| 18 Feb 2026filed 20 Feb 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code F | $4.3M357,678 at $11.93 | filing |
| 13 Oct 2025filed 15 Oct 2025 | OMER OmerosBiotechnology | SEC FORM 4 Code G | —600,000 at $0.00 | filing |
| 13 Oct 2025filed 15 Oct 2025 | OMER OmerosBiotechnology | SEC FORM 4 Code G | —300,000 at $0.00 | filing |
| 13 Oct 2025filed 15 Oct 2025 | OMER OmerosBiotechnology | SEC FORM 4 Code G | —300,000 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —865,000 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —725,000 at $0.00 | filing |
| 17 Nov 2023filed 21 Nov 2023 | OMER OmerosBiotechnology | SEC FORM 4 Bought | $25K15,000 at $1.68 | filing |
| 14 Nov 2023filed 15 Nov 2023 | OMER OmerosBiotechnology | SEC FORM 4 Code A | $36K25,000 at $1.44 | filing |
| 13 Nov 2023filed 15 Nov 2023 | OMER OmerosBiotechnology | SEC FORM 4 Code A | $48K37,500 at $1.29 | filing |
| 22 Sep 2023filed 27 Sep 2023 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —715,000 at $0.00 | filing |
| 21 Sep 2022filed 23 Sep 2022 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 2 Jul 2021filed 6 Jul 2021 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 17 Jun 2021filed 17 Jun 2021 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,857 at $0.00 | filing |
News
Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab OpinionOMER · rttnews.com · 16 Oct 2026
0 headlines in the last 90 days name Gregory A. Demopulos; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.